Prestige Consumer Healthcare Inc.
PBH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PBH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PBH
Prestige Consumer Healthcare Inc. (PBH) is a marketer and distributor of over-the-counter (OTC) healthcare products in North America and internationally, with a portfolio spanning analgesics, cough & cold, and other consumer health categories.
Key risk: Declining North American OTC revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.49B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Prestige Consumer Healthcare Inc. (PBH) is a marketer and distributor of over-the-counter (OTC) healthcare products in North America and internationally, with a portfolio spanning analgesics, cough & cold, and other consumer health categories.
- Revenue for fiscal year 2025 was $1,138M with organic growth of 1.2% [sec · filed 2025-06-27].
- Adjusted diluted EPS for fiscal 2025 was $4.52, representing 7.3% growth [sec · filed 2025-06-27].
- Free cash flow for fiscal 2025 was approximately $243M [sec · filed 2025-06-27].
- As of June 30, 2026, cash and cash equivalents were $89.1M, total debt was $27.7M, and shareholders' equity was $1,887.5M [sec_mda · as of 2026-08-06].
- The company reduced debt to its lowest level in company history during fiscal 2025 [sec · filed 2025-06-27].
What works
- Strong free cash flow generation of approximately $243M in fiscal 2025 supports capital allocation flexibility [sec · filed 2025-06-27].
- Low debt levels relative to equity (total debt $27.7M vs. equity $1,887.5M as of June 30, 2026) provide financial stability [sec_mda · as of 2026-08-06].
- Consistent profitability with adjusted EPS growth of 7.3% in fiscal 2025 [sec · filed 2025-06-27].
What to weigh
- Revenue in the North American OTC segment declined in key categories: analgesics fell 3.5% and cough & cold fell 6.9% in fiscal 2026 compared to fiscal 2025 [sec_mda · as of 2026-05-14].
- Cash and cash equivalents decreased from $139.5M (June 30, 2025) to $89.1M (June 30, 2026), a decline of $50.4M [sec_mda · as of 2025-08-07] [sec_mda · as of 2026-08-06].
- The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash and cash equivalents as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $89.1 million”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- Declining North American OTC revenue — Analgesics and cough & cold segments saw revenue declines of 3.5% and 6.9% respectively in fiscal 2026 vs. 2025 [sec_mda · as of 2026-05-14].
- Cash reserve reduction — Cash and equivalents fell from $139.5M (June 30, 2025) to $89.1M (June 30, 2026), a 36% decrease [sec_mda · as of 2025-08-07] [sec_mda · as of 2026-08-06].
- Forward-looking uncertainties — Company cautions that forward-looking statements involve risks and uncertainties that could cause actual results to differ [sec_mda · as of 2026-08-06].
What to watch
- Trend in North American OTC segment revenue, particularly analgesics and cough & cold categories [sec_mda · as of 2026-05-14].
- Cash and debt levels in upcoming quarterly filings to assess financial flexibility [sec_mda · as of 2026-08-06].
- Any updates on capital allocation priorities, including share repurchases or acquisitions [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Prestige Consumer Healthcare Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Prestige Consumer Healthcare Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.38 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
350
Total value held
$3.04B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,388,490 | $437.9M |
| ariel investments, llc | 4,274,326 | $253.3M |
| vanguard capital management llc | 4,185,986 | $248.1M |
| vanguard portfolio management llc | 2,803,828 | $166.2M |
| dimensional fund advisors lp | 2,672,777 | $158.4M |
| kayne anderson rudnick investment management llc | 2,202,606 | $130.5M |
| state street corp | 1,970,981 | $116.8M |
| geode capital management, llc | 1,460,035 | $86.5M |
| morgan stanley | 1,357,470 | $80.5M |
| westwood holdings group inc | 1,119,715 | $66.4M |
Showing top 10 of 350 institutional holders of Prestige Consumer Healthcare Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 8.0%
- Days to cover
- 5.8
- Shares short
- 2,692,183
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PBH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Prestige Consumer Healthcare Inc.?
Prestige Consumer Healthcare Inc. (PBH) is a marketer and distributor of over-the-counter (OTC) healthcare products in North America and internationally, with a portfolio spanning analgesics, cough & cold, and other consumer health categories.
Who is the CEO of Prestige Consumer Healthcare Inc.?
Mr. Ronald M. Lombardi C.P.A. is the chief executive officer of Prestige Consumer Healthcare Inc. (PBH).
Where is Prestige Consumer Healthcare Inc. headquartered?
Prestige Consumer Healthcare Inc. (PBH) is headquartered in Tarrytown, NY, United States.
What therapeutic areas does Prestige Consumer Healthcare Inc. focus on?
Prestige Consumer Healthcare Inc. develops therapies across Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.